Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

cancer

Aliases
Advanced Solid Tumors

362 clinical trials

374 products

50 drugs

Clinical trial
A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-31
Product
SGN-PDL1V
Product
pembrolizumab
Product
Pembrolizumab
Product
Paclitaxel
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations Who Have Disease Control After an 8-Week Lead-In Treatment With Erlotinib
Status: Active (not recruiting), Estimated PCD: 2016-03-14
Product
Erlotinib
Clinical trial
Managed Access Program (MAP) Cohort Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)
Status:
Product
Capmatinib
Product
LY2875358
Product
Bevacizumab
Product
Docetaxel
Clinical trial
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Status: Terminated, Estimated PCD: 2023-06-02
Clinical trial
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy.
Status: Completed, Estimated PCD: 2023-05-31
Product
Durvalumab
Product
CT-0508
Product
SGN-STNV
Clinical trial
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2024-03-01
Product
Atezolizumab
Clinical trial
A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
Status: Active (not recruiting), Estimated PCD: 2024-08-13
Clinical trial
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1)
Status: Completed, Estimated PCD: 2023-08-31
Clinical trial
A Phase I/III, Multi-center, Randomized, Double-blind Study of BAT3306 Plus Chemotherapy Versus Keytruda® Plus Chemotherapy to Evaluate Pharmacokinetics, Efficacy, and Safety in Participants With Stage IV Non-squamous Non-small Cell Lung Cancer.
Status: Not yet recruiting, Estimated PCD: 2027-07-30
Product
EU-Keytruda®
Clinical trial
A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Status: Completed, Estimated PCD: 2023-09-12
Product
BAT3306
Product
US-Keytruda®
Product
Pemetrexed
Product
Carboplatin
Product
palbociclib
Product
Nivolumab
Clinical trial
A Phase III, Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
Status: Active (not recruiting), Estimated PCD: 2023-02-02
Clinical trial
Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Status: Active (not recruiting), Estimated PCD: 2024-08-23
Clinical trial
A Phase Ib/II Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Status: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Stage 4 Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Ribociclib
Clinical trial
KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Status: Recruiting, Estimated PCD: 2027-05-05
Product
SGN-ALPV
Clinical trial
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-12-13
Product
cetuximab
Clinical trial
A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)
Status: Active (not recruiting), Estimated PCD: 2020-12-31
Clinical trial
An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
TAK-676
Clinical trial
A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of ZN-e4 (KP-673) in Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor (EGFR) Mutations
Status: Completed, Estimated PCD: 2022-01-17
Product
nivolumab
Product
ipilimumab
Product
ZN-e4
Product
KB-GDT-01
Clinical trial
An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 765063 and [89Zr]Zr-BI 770371 in Patients With Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer or Melanoma Who Are Treated With Ezabenlimab
Status: Recruiting, Estimated PCD: 2024-07-12
Product
BI 765063
Product
BI 770371
Product
MORAb-066
Product
BCA101
Clinical trial
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2019-04-01
Product
Ipilimumab
Product
Ezabenlimab
Product
TRX-221
Product
Cisplatin
Clinical trial
An Open Label, Multicenter, Phase 1/2 Study to Explore the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of TRX-221 in the Treatment of Patients With EGFR Mutant NSCLC Who Progressed Following Prior Therapy With EGFR TKI
Status: Not yet recruiting, Estimated PCD: 2027-06-30
Clinical trial
A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-066, a Humanized Monoclonal Antibody to Human Tissue Factor, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or Non-Small Cell Lung Cancer (Adenocarcinoma) Malignancies
Status: Completed, Estimated PCD: 2016-02-09
Product
lenvatinib
Product
Saline Placebo
Product
treatment
Clinical trial
Vargatef in 2nd-line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Tremelimumab
Product
BIO 300
Product
Oregovomab
Clinical trial
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-09-26
Product
Quaratusugene Ozeplasmid
Clinical trial
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Platinum-Based Chemotherapy
Clinical trial
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Status: Completed, Estimated PCD: 2023-04-12
Product
Lorlatinib
Product
JDQ443
Product
trametinib
Product
BLU-451
Clinical trial
Single-Arm Study of Lorlatinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI)
Status: Active (not recruiting), Estimated PCD: 2024-06-25
Product
BA3071
Clinical trial
A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-30
Product
NKT2152
Clinical trial
A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination With Palbociclib (Doublet) and With Palbociclib and Sasanlimab (Triplet) in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-06-01
Product
osimertinib
Product
Placebo
Product
Cabozantinib
Clinical trial
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma (LEAP-002)
Status: Active (not recruiting), Estimated PCD: 2022-06-21
Product
Etoposide
Product
XNW5004
Clinical trial
A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment
Status: Active (not recruiting), Estimated PCD: 2023-01-03
Clinical trial
A Multicentre, Observational, Phase 4 Study to Evaluate the Safety and Tolerability of Lenvatinib in Patients With Advanced or Unresectable Hepatocellular Carcinoma (STELLAR)
Status: Active (not recruiting), Estimated PCD: 2031-03-07
Product
Sorafenib
Product
Lenvatinib
Clinical trial
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients With EGFR Mutant Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Product
Spartalizumab
Product
AFM24
Clinical trial
A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
Status: Terminated, Estimated PCD: 2023-09-21
Clinical trial
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03B
Status: Active (not recruiting), Estimated PCD: 2025-09-07
Product
MK-4830
Product
Belzutifan
Product
Pembrolizumab/Quavonlimab
Product
Favezelimab/Pembrolizumab
Clinical trial
A Phase 1 Study of SGN-EGFRd2 in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-07-31
Clinical trial
A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy and Anti-PD-1 (L)1 Immunotherapy
Status: Withdrawn, Estimated PCD: 2023-12-17
Product
docetaxel
Product
lucitanib
Clinical trial
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior Generation EGFR-TKI Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)
Status: Terminated, Estimated PCD: 2022-12-27
Product
Osimertinib
Product
SGN-EGFRd2
Clinical trial
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study (AHELP) of Apatinib in Patients With Hepatocellular Carcinoma After Systemic Therapy（Chemotherapy and/or Targeted Therapy）
Status: Completed, Estimated PCD: 2017-12-15
Clinical trial
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Status: Completed, Estimated PCD: 2018-04-30
Product
Efineptakin alfa
Product
Apatinib
Product
afatinib
Clinical trial
A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
GNR-051
Clinical trial
A Multinational, Multicenter, Phase III, Randomized Open-label Trial of Pembrolizumab Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2019-09-09
Clinical trial
A Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 (GENERIUM JSC, Russia) in Subjects With Solid Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2022-11-07
Clinical trial
A Phase IIIb, Single Arm, Multicenter Study of Atezolizumab in Combination With Bevacizumab to Investigate Safety and Efficacy in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
Status: Active (not recruiting), Estimated PCD: 2024-04-27
Product
cabozantinib
Product
ramucirumab
Product
SNK01
Clinical trial
A Phase 1, Open-Label, Multicenter, Drug-Drug Interaction Study of TAK-788 and Midazolam, a Sensitive CYP3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2020-12-17
Product
TAK-788
Product
Durvalumab + SoC chemotherapy
Clinical trial
A Double-blind, Placebo Controlled, Randomized, Phase II Study Evaluating the Efficacy and Safety of Capmatinib and Spartalizumab vs Capmatinib and Placebo as 1st Line Treatment for Advanced NSCLC Patients With MET exon14 Skipping Mutations
Status: Terminated, Estimated PCD: 2022-12-14
Clinical trial
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)
Status: Recruiting, Estimated PCD: 2024-11-01
Product
Midazolam
Product
LP-300
Clinical trial
Phase II, Single-Arm Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2022-06-21
Clinical trial
A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
LOXO-260
Product
BLU-945
Product
DFF332
Clinical trial
Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
Status: Terminated, Estimated PCD: 2014-07-23
Product
Lazertinib
Product
E7386
Clinical trial
A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients With EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2021-01-08
Product
Selpercatinib
Clinical trial
An Open-label Phase 1b Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
Status: Recruiting, Estimated PCD: 2027-03-15
Product
Saline
Clinical trial
An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-07-16
Clinical trial
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
Status: Active (not recruiting), Estimated PCD: 2025-02-28
Product
Tiragolumab
Clinical trial
A First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 765049 and BI 765049 + BI 754091 Administered by Parental Administration(s) in Patients With Malignant Solid Tumors Expressing B7-H6
Status: Recruiting, Estimated PCD: 2025-12-23
Product
ezabenlimab
Clinical trial
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Status: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy
Status: Active (not recruiting), Estimated PCD: 2032-02-13
Product
Savolitinib
Clinical trial
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Active (not recruiting), Estimated PCD: 2019-08-18
Clinical trial
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2023-09-21
Product
diphenhydramine
Product
acetaminophen
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Status: Recruiting, Estimated PCD: 2025-04-30
Product
MK-0482
Clinical trial
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-07-26
Product
RAD001
Product
PDR001
Product
NIR178
Clinical trial
A Randomized, Double-blind, Multi-center, Phase II Study to Evaluate the Anti-tumor Efficacy, Safety and Tolerability of HLX53 (an Anti-TIGIT Fc Fusion Protein) Combined With Serplulimab Injection (HLX10, a Recombinant Anti-PD-1 Antibody) and HLX04 (a Biosimilar to Bevacizumab) Compared to Placebo + Serplulimab + HLX04, in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Status: Not yet recruiting, Estimated PCD: 2027-02-10
Product
HLX53
Product
HLX10
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC)
Status: Recruiting, Estimated PCD: 2025-09-30
Product
Sunitinib
Clinical trial
A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2021-11-04
Product
Mocetinostat
Clinical trial
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)
Status: Recruiting, Estimated PCD: 2027-01-12
Clinical trial
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Status: Active (not recruiting), Estimated PCD: 2022-10-21
Product
BI 765049
Product
Hyperpolarized xenon MRI
Clinical trial
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Status: Active (not recruiting), Estimated PCD: 2020-03-20
Product
Crizotinib
Clinical trial
A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy
Status: Active (not recruiting), Estimated PCD: 2024-06-21
Clinical trial
A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Boserolimab
Product
Tobemstomig
Clinical trial
A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2027-05-01
Product
HLX04
Product
NRC-2694-A
Clinical trial
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
Status: Recruiting, Estimated PCD: 2027-03-22
Product
Nab-paclitaxel
Product
Olaparib
Clinical trial
Development and Analysis of a Sample Bank (Blood, Urine, and Stool) for Cancer Patients, Enabling the Systematic Study of the Effect of Blood, Urinary Tract, and Gut Microbiomes on Response to Treatment
Status: Recruiting, Estimated PCD: 2028-12-31
Product
Glesatinib
Product
Sitravatinib
Clinical trial
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Sacituzumab Govitecan
Clinical trial
A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant V940 (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007)
Status: Recruiting, Estimated PCD: 2029-04-30
Product
V940
Clinical trial
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
Status: Recruiting, Estimated PCD: 2027-08-31
Product
Dasatinib
Product
Keytruda
Product
Tisotumab vedotin
Product
Vobramitamab Duocarmazine
Product
Vobramitamab
Clinical trial
A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Status: Recruiting, Estimated PCD: 2027-01-08
Product
TNO155
Product
tislelizumab
Product
Relatlimab
Clinical trial
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Status: Active (not recruiting), Estimated PCD: 2026-10-29
Product
SGN-B7H4V
Clinical trial
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab in Combination With Chemotherapy in Treatment-Naive Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2039-02-13
Clinical trial
A Phase III, Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab Given in Combination With Cabozantinib Versus Docetaxel Monotherapy in Patients With Metastatic Non-Small Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2022-09-28
Clinical trial
A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma
Status: Recruiting, Estimated PCD: 2024-06-04
Clinical trial
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2023-05-17
Product
Binimetinib
Product
Axitinib
Clinical trial
Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases
Status: Recruiting, Estimated PCD: 2027-12-01
Product
SEA-CD40
Product
pemetrexed
Product
carboplatin
Clinical trial
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-01-03
Clinical trial
A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-09-12
Clinical trial
A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Japanese Patients With Primary Advanced or Recurrent Endometrial Cancer (RUBY-J)
Status: Not yet recruiting, Estimated PCD: 2026-07-15
Product
Dostarlimab
Clinical trial
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-02-10
Clinical trial
Expanded Access of LOXO-260 in Participants With RET Mutant or RET Fusion Tumors Refractory to Prior RET Selective TKI Treatment
Status:
Product
BT8009
Product
AZD7789
Product
PF-00299804
Clinical trial
Phase 1 Targeted Combination Trial Of PF-00299804 And CP-751,871 In Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2011-08-09
Product
cisplatin
Clinical trial
A PHASE 2, MULTI-CENTER, OPEN-LABEL, DUAL-COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORLATINIB (PF-06463922) MONOTHERAPY IN ALK INHIBITOR-TREATED LOCALLY ADVANCED OR METASTATIC ALK-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS IN CHINA
Status: Active (not recruiting), Estimated PCD: 2020-08-10
Clinical trial
A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
Status: Recruiting, Estimated PCD: 2026-02-20
Product
SGN-CEACAM5C
Product
Avelumab
Clinical trial
A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
Status: Completed, Estimated PCD: 2019-05-02
Product
Quaratusugene
Clinical trial
A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON).
Status: Recruiting, Estimated PCD: 2027-08-17
Product
Datopotamab Deruxtecan
Product
KB707
Clinical trial
Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours (TROPION-PanTumor02)
Status: Active (not recruiting), Estimated PCD: 2023-11-07
Clinical trial
KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Treatment Naïve Patients With PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2025-09-17
Product
PF-07284890
Clinical trial
A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF 07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT
Status: Terminated, Estimated PCD: 2024-03-20
Product
Entrectinib
Clinical trial
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-03-21
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Status: Active (not recruiting), Estimated PCD: 2025-05-05
Clinical trial
A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.
Status: Recruiting, Estimated PCD: 2024-08-23
Product
savolitinib
Clinical trial
A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-01-09
Product
placebo
Product
Encorafenib
Product
Sasanlimab
Product
SEA-TGT
Product
Tisotumab Vedotin
Product
DKY709
Clinical trial
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors.
Status: Recruiting, Estimated PCD: 2025-07-29
Product
KFA115
Clinical trial
An Open-label Phase 1 Study to Investigate SGN-CEACAM5C in Adults With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2029-03-31
Clinical trial
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2026-07-06
Product
Vibostolimab
Product
QEQ278
Product
Pralsetinib
Clinical trial
A Three Arm, Randomized, Double-Blind, Multicenter, Phase 3 Study of HLX10(Anti-PD-1 Antibody) in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04(Avastin Biosimilar) Compared With Carboplatin+Pemetrexed in 1L Stage IIIB/IIIC or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2023-10-01
Clinical trial
An Open-label, Multicenter, Phase 1/2 Study of Radium-223 Dichloride in Combination With Pembrolizumab in Participants With Stage IV Non-small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2021-04-14
Clinical trial
A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-13
Product
CC-486
Clinical trial
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2017-04-13
Clinical trial
A Phase 1, Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Status: Active (not recruiting), Estimated PCD: 2025-07-17
Clinical trial
A Phase II Study of Intratumoral Administration of L19IL2/L19TNF in Non-melanoma Skin Cancer Patients With Presence of Injectable Lesions
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
STAR-TOR- REGISTRY FOR THE EVALUATION OF THE SAFETY, TOLERABILITY AND EFFICACY OF TEMSIROLIMUS (TORISEL), SUNITINIB (SUTENT) AND AXITINIB (INLYTA) FOR THE TREATMENT OF SUBJECTS WITH ADVANCED RENAL CELL CARCINOMA (MRCC), MANTLE CELL LYMPHOMA (MCL) AND GASTRO-INTESTINAL STROMA TUMOR (GIST).
Status: Completed, Estimated PCD: 2021-12-28
Product
Temsirolimus
Product
Immuncell-LC
Clinical trial
Randomized, Open-label, Multi-center and Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in the Patients Undergone TACE for Intermediate Stage Hepatocellular Carcinoma
Status: Completed, Estimated PCD: 2020-08-11
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-02
Product
PTX-9908
Clinical trial
Phase I/II Study of PTX-9908 Injection as an Inhibitor of Cancer Progression in Patients With Non-resectable Hepatocellular Carcinoma Following Transarterial Chemoembolization Treatment
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Phase III Randomized Double-blind Study of Pembrolizumab Plus Best Supportive Care vs. Placebo Plus Best Supportive Care as Second-Line Therapy in Asian Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-394)
Status: Active (not recruiting), Estimated PCD: 2021-06-30
Product
CAN04
Clinical trial
An Open-label, Safety and Tolerability Phase 1b Trial of CAN04, a Fully Humanized Anti-IL1RAP Monoclonal Antibody, and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Status: Completed, Estimated PCD: 2023-06-28
Clinical trial
A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2022-12-09
Clinical trial
A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular Carcinoma
Status: Completed, Estimated PCD: 2022-12-28
Product
Oxaliplatin
Product
Folinic acid
Product
5-FU
Product
ASN003
Clinical trial
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2019-02-01
Clinical trial
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy
Status: Completed, Estimated PCD: 2020-10-27
Product
Enfortumab vedotin
Clinical trial
A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer
Status: Active (not recruiting), Estimated PCD: 2026-12-31
Clinical trial
A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-10-25
Clinical trial
A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Status: Terminated, Estimated PCD: 2022-05-16
Clinical trial
A Phase 2, Open-label, Randomized, Parallel Group, Controlled Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus-Positive, Non-Squamous, Non-Small Cell Lung Carcinoma Following First-Line Induction Chemotherapy
Status: Withdrawn, Estimated PCD: 2019-03-01
Clinical trial
Phase 1b/2a Safety and Tolerability Study of Bemcentinib With Pembrolizumab/Carboplatin/Pemetrexed in Subjects With Untreated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Without/With a STK11 Mutation
Status: Recruiting, Estimated PCD: 2025-08-11
Product
Dabrafenib
Product
Trametinib
Product
RO7119929
Product
Tocilizumab
Product
TAK-659
Product
Amivantamab
Clinical trial
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)
Status: Active (not recruiting), Estimated PCD: 2028-06-30
Product
IV Placebo
Clinical trial
A Phase 1/2 Open-label Trial of KVA12123 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-30
Product
KVA12123 Plus Pembrolizumab
Product
tucatinib
Product
trastuzumab
Clinical trial
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2018-11-30
Clinical trial
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic HCC or GC/GEJC
Status: Completed, Estimated PCD: 2023-03-31
Product
Sitravatinib + Tislelizumab
Product
fulvestrant
Product
Recombinant oncolytic herpes simplex virus type 1 (R130)
Product
Jelmyto
Clinical trial
An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
Afatinib
Product
Palbociclib
Drug
standard of care
Product
IPH2201
Drug
AN0025
Product
Niraparib
Product
INCAGN01876
Clinical trial
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-08-01
Product
DNA Extraction
Clinical trial
TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES). Phase II Clinical Trial, Single Arm, Two Stage
Status: Terminated, Estimated PCD: 2017-02-21
Product
ARQ197
Clinical trial
A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2019-01-09
Drug
Gemcitabine
Clinical trial
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Status: Terminated, Estimated PCD: 2023-03-06
Product
BP1001-A
Clinical trial
A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies
Status: Active (not recruiting), Estimated PCD: 2025-09-17
Product
Everolimus
Clinical trial
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A
Status: Active (not recruiting), Estimated PCD: 2026-05-31
Clinical trial
A Multicenter, Observational Study to Describe the Effectiveness and Treatment Patterns of Dacomitinib Among Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Patients With Brain Metastasis
Status: Not yet recruiting, Estimated PCD: 2026-09-07
Clinical trial
A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Status: Completed, Estimated PCD: 2021-12-06
Product
Irinotecan
Product
Sigvotatug Vedotin
Clinical trial
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-11-30
Clinical trial
An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Status: Recruiting, Estimated PCD: 2029-02-26
Clinical trial
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)
Status: Recruiting, Estimated PCD: 2026-10-01
Product
Tivozanib
Clinical trial
A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma
Status: Completed, Estimated PCD: 2018-10-04
Product
Brigatinib
Clinical trial
TATE Versus TACE, an Open-label Randomized Study Comparing TransArterial Tirapazamine Embolization Versus TransArterial ChemoEmbolization in Intermediate Stage Hepatocellular Carcinoma
Status: , Estimated PCD: 2024-12-31
Product
Doxorubicin
Clinical trial
A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination With Nivolumab in Subjects With Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Terminated, Estimated PCD: 2022-01-24
Clinical trial
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Status: Completed, Estimated PCD: 2022-09-29
Product
G1T48
Clinical trial
A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung
Status: Completed, Estimated PCD: 2022-04-22
Product
VTX-2337
Product
Gemcitabine
Clinical trial
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-03-28
Product
Parvovirus H-1
Product
Regorafenib
Clinical trial
A Multicenter, Non-randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma (HCC) With no Prior Systemic Therapy
Status: Completed, Estimated PCD: 2020-12-17
Clinical trial
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
Status: Completed, Estimated PCD: 2019-08-01
Clinical trial
An Expanded Access Protocol for Mobocertinib in Refractory Non-Small Cell Lung Cancer Patients With EGFR exon20 Insertion Mutations
Status:
Clinical trial
An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210(Anti-PD-1 Antibody) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2020-08-20
Clinical trial
A Real World Retrospective Database Study of Patients Diagnosed With Metastatic and/or Advanced Renal Cell Carcinoma and Treated With Sunitinib and/or Axitinib in a Specialist United Kingdom Oncology Centre
Status: Completed, Estimated PCD: 2020-12-18
Product
Oleclumab
Clinical trial
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Status: Completed, Estimated PCD: 2022-07-22
Clinical trial
A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy
Status: Completed, Estimated PCD: 2020-10-27
Product
Chemotherapy
Product
Mobocertinib
Clinical trial
A Retrospective Registry Based Study for Evaluating Treatment Response in Patients Targeted Treated With Metastatic Renal Cell Carcinoma (mRCC) With Sunitinib in First-line Therapy
Status: Completed, Estimated PCD: 2023-02-23
Clinical trial
An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients With Non-small Cell Lung Cancer and Other Solid Tumors
Status: Completed, Estimated PCD: 2023-03-09
Product
BI 754091
Product
99mTc-Macro Albumin Aggregate
Product
LTX-315
Clinical trial
A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-06-30
Product
gemcitabine
Clinical trial
Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2010-12-15
Product
Panitumumab
Clinical trial
A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Status: Completed, Estimated PCD: 2020-03-01
Clinical trial
A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (METΔex14).
Status: Completed, Estimated PCD: 2023-02-15
Clinical trial
uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Alectinib
Clinical trial
A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients With Advanced Basal Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)
Status: Completed, Estimated PCD: 2020-09-01
Product
CX-4945
Clinical trial
A First In Human, Open Label, Dose Escalation Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Clinical Activity Profile Of Single Agent RO7119929 (TLR7 Agonist) Administered Orally To Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Status: Completed, Estimated PCD: 2023-01-09
Product
Bemcentinib
Clinical trial
A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2017-04-24
Clinical trial
A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
Status: Recruiting, Estimated PCD: 2021-11-18
Product
Napabucasin
Clinical trial
A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung Cancer
Status: Completed, Estimated PCD: 2022-07-29
Product
M7824
Clinical trial
A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
Status: Terminated, Estimated PCD: 2023-10-10
Clinical trial
An Open-Label, Single-arm Study to Evaluate the Safety and Efficacy of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-21
Clinical trial
A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 With or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2024-06-30
Product
ST-067
Product
Obinutuzumab
Product
Rhenium
Clinical trial
A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Completed, Estimated PCD: 2020-08-31
Clinical trial
A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy In Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC): Abound.2L+
Status: Completed, Estimated PCD: 2017-07-17
Product
AZD8853
Clinical trial
A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Status: Terminated, Estimated PCD: 2023-06-06
Clinical trial
A Phase II Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With Locally Advanced Head and Neck Cancer (CTRC# 11-36)
Status: Completed, Estimated PCD: 2022-10-04
Clinical trial
Synergistic Real-World Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors（TKIs）in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): Prospective Study
Status: Recruiting, Estimated PCD: 2025-09-30
Product
Elemene
Product
EGFR-TKIs
Clinical trial
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-02-01
Drug
LY3537982
Clinical trial
Phase II Study of Neoadjuvant Atezolizumab-based Immunotherapy for Patients With Urothelial Carcinoma (NEBULA)
Status: Completed, Estimated PCD: 2023-03-31
Drug
Atezolizumab
Clinical trial
A Prospective, Pilot Study of First-line Osimertinib With or Without Savolitinib in de Novo MET Positive, EGFR-mutant NSCLCs (FLOWERS)
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Drug
Osimertinib
Clinical trial
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Drug
Pralsetinib
Drug
Cisplatin
Product
Fludarabine
Product
Cyclophosphamide
Product
CISH Inactivated TIL
Product
Aldesleukin
Product
Vinorelbine
Product
Doxil
Product
Taxane
Product
Nab-Paclitaxel
Product
Vibostolimab/Pembrolizumab
Product
dacomitnib
Product
Disitamab vedotin
Clinical trial
A Randomized, Phase 3, Open-label Study to Evaluate SGN-B6A Compared With Docetaxel in Adult Subjects With Previously Treated Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-07-31
Clinical trial
A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
Status: Recruiting, Estimated PCD: 2026-05-31
Product
AB-1015
Product
Repotrectinib
Product
STAR0602
Product
Sotatercept
Clinical trial
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors
Status: Completed, Estimated PCD: 2020-03-24
Product
Tirapazamine
Product
Duravalumab
Product
Radium-223 dichloride
Product
L19IL2 +L19TNF
Clinical trial
An Open-Label Randomized, Phase 2A, Dose-Ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Terminated, Estimated PCD: 2012-09-21
Clinical trial
A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer
Status: Completed, Estimated PCD: 2018-05-01
Product
SHR-1210
Product
G1T38
Product
MORAb-202
Clinical trial
Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer After Endocrine Failure
Status: Active (not recruiting), Estimated PCD: 2023-06-01
Product
Fulvestrant
Clinical trial
Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination With Osimertinib in Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2021-12-14
Clinical trial
A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
Status: Terminated, Estimated PCD: 2019-11-30
Product
Rogaratinib
Product
RRx-001
Clinical trial
A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies
Status: Recruiting, Estimated PCD: 2024-03-04
Product
BI 754111
Product
BLU-701
Clinical trial
A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 2 Study to Investigate the Efficacy and Safety of Atezolizumab With or Without Tiragolumab as Consolidation Therapy in Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed After Chemoradiotherapy
Status: Terminated, Estimated PCD: 2023-07-25
Clinical trial
Study to Calculate the Radiation-Absorbed Dose of Technetium-99m Macroaggregated Albumin (99mTc-MAA) to the Whole Body and Non-Liver Critical Organs
Status: Completed, Estimated PCD: 2023-07-05
Product
VP-315
Clinical trial
A Single Arm, Phase II Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Pretreated With Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitors
Status: Completed, Estimated PCD: 2022-01-19
Product
ADXS11-001
Product
cemiplimab
Product
CK-301
Product
KVA12123
Clinical trial
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Status: Completed, Estimated PCD: 2021-05-20
Clinical trial
A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects With Unresectable or Metastatic Melanoma or PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593)
Status: Active (not recruiting), Estimated PCD: 2024-07-22
Product
Bintrafusp alfa
Clinical trial
A Prospective, Multicenter, Post-marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Completed, Estimated PCD: 2023-07-31
Product
Oral Placebo
Product
Sitravatinib and Tislelizumab
Product
Zirconium-89 Crefmirlimab Berdoxam
Clinical trial
Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
Status: Recruiting, Estimated PCD: 2009-06-20
Clinical trial
An Open, Single-armed, Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2033-12-30
Product
Montanide ISA-51 VG
Clinical trial
A Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-06-30
Product
Carboplatin/Cisplatin
Clinical trial
Evaluation of 68GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients
Status: Recruiting, Estimated PCD: 2026-09-01
Product
68GaNOTA-Anti-HER2
Clinical trial
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: a Multicentre, Pragmatic Randomized Trial
Status: Recruiting, Estimated PCD: 2027-08-01
Product
Nicotinamide
Clinical trial
A Phase II Trial of High-Dose Ascorbate in Stage IV Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2021-12-01
Drug
Tiragolumab
Product
Ascorbic Acid
Clinical trial
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
Status: Active (not recruiting), Estimated PCD: 2024-12-23
Clinical trial
Standard Dosed Alectinib Versus Therapeutic Drug Monitoring Guided Alectinib Dosing
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Status: Completed, Estimated PCD: 2020-06-08
Product
Cetuximab
Product
PD 0332991
Clinical trial
National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
AZD5363
Drug
Sitravatinib
Drug
Ceralasertib
Clinical trial
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC
Status: Recruiting, Estimated PCD: 2028-09-01
Product
pembrolizumab/vibostolimab
Drug
durvalumab
Drug
pemetrexed
Drug
etoposide
Drug
carboplatin
Drug
paclitaxel
Clinical trial
Phase I/II Study Assessing Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Primary Lung Cancer With Durvalumab After Definitive Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Randomized Placebo-controlled Phase III Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene
Status: Not yet recruiting, Estimated PCD: 2027-07-13
Clinical trial
Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer
Status: Completed, Estimated PCD: 2022-09-06
Clinical trial
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
Status: Completed, Estimated PCD: 2022-12-26
Drug
mFOLFOX6
Clinical trial
An Open-label, Single-arm, Multicenter, Prospective Study of Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients With Advanced Small Cell Lung Cancer That Progressed Following Prior Therapy With Platinum-Based Chemotherapy.
Status: Recruiting, Estimated PCD: 2025-05-01
Product
PM 01183
Clinical trial
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2022-04-05
Clinical trial
A Single-arm Phase 2 Study of Sugemalimab and Chemotherapy as Induction Therapy in Unresectable and Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Sugemalimab
Clinical trial
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-06-30
Product
Cetrelimab
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Product
Cobimetinib
Product
RO6958688
Drug
Docetaxel
Product
CPI-444
Product
Linagliptin
Clinical trial
Phase I Study of MOC31-PE in Antigen Positive Carcinomas
Status: Completed, Estimated PCD: 2012-02-01
Product
MOC31-PE
Clinical trial
Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent.
Status: Completed, Estimated PCD: 2020-06-01
Clinical trial
Concurrent Nab--paclitaxel/Carboplatin and Thoracic Radiotherapy in Inoperable Stage III Squamous Cell Lung Cancer
Status: Terminated, Estimated PCD: 2021-12-12
Drug
Abraxane
Clinical trial
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
Status: Not yet recruiting, Estimated PCD: 2024-06-01
Drug
Adebrelimab
Drug
PD-1 antibody
Clinical trial
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative：A Multi-center, Single-arm, Phase II Study
Status: Recruiting, Estimated PCD: 2025-08-31
Drug
Cadonilimab
Clinical trial
Prospective, Single-arm, Multicenter Phase II Study of Evaluation of the Efficacy and Safety of Pemigatinib Combined With PD-1 Inhibitor in First-line Treatment of Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Status: Recruiting, Estimated PCD: 2024-11-01
Product
Pemigatinib
Clinical trial
A Prospective, National, Multi-centric, Non-interventional Study of First Line Osimertinib in Chinese Patients With Locally Advanced/Metastatic，EGFR Mutation-positive NSCLC in Real World Setting
Status: Active (not recruiting), Estimated PCD: 2022-04-26
Clinical trial
Personalized Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Phase 2 Study
Status: Recruiting, Estimated PCD: 2025-04-12
Product
177Lu-Octreotate
Clinical trial
GDF15 (Growth Differentiation Factor 15) Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at T3/T4cN0M0 Stage: a Phase II Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2023-12-31
Product
TPF induction chemotherapy
Clinical trial
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC
Status: Terminated, Estimated PCD: 2021-10-22
Product
Platinum Based Chemotherapy
Clinical trial
Tyrosine Kinase Inhibitors in the Management of Local Advanced or Metastastic Adenoid Cystic Carcinoma
Status: Recruiting, Estimated PCD: 2024-07-31
Product
EGFR-TK Inhibitor
Clinical trial
A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers
Status: Completed, Estimated PCD: 2019-06-20
Product
rh IL-15
Clinical trial
A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Active (not recruiting), Estimated PCD: 2023-08-31
Drug
Nab-Paclitaxel
Clinical trial
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers: Phase 2 Randomized Trial (VALUE-CHECK)
Status: Not yet recruiting, Estimated PCD: 2029-03-30
Product
Extended Dosing Interval
Product
Standard of Care
Clinical trial
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Status: Not yet recruiting, Estimated PCD: 2027-07-30
Clinical trial
Testing the Ability of Immunotherapy to Alter the Tumor Immune MicroEnvionment (TIME) and Reduce or Eradicate High Risk DCIS
Status: Recruiting, Estimated PCD: 2025-03-31
Product
Intralesional mRNA 2752
Clinical trial
Paediatric Hepatic International Tumour Trial
Status: Active (not recruiting), Estimated PCD: 2026-08-01
Drug
R-CHOP
Product
5Fluorouracil
Drug
mFOLFOXIRI
Clinical trial
Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY): a Prospective Single Center, Open Label, Phase II Study
Status: Not yet recruiting, Estimated PCD: 2025-02-28
Drug
Anlotinib
Product
Zoledronic Acid
Clinical trial
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations
Status: Recruiting, Estimated PCD: 2025-03-05
Product
Denosumab
Clinical trial
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Status: Completed, Estimated PCD: 2021-12-30
Product
Sintilimab
Clinical trial
A Window of Opportunity Trial With Meclizine in Hepatocellular Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
Meclizine
Clinical trial
Preoperative Stereotactic Body Radiotherapy and Platinum-based Doublet Chemotherapy Plus Tislelizumab (Immunotherapy) for Operable Stage II to III EGFR Wild-type Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-06-25
Product
Tislelizumab
Clinical trial
A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC
Status: Recruiting, Estimated PCD: 2026-04-28
Clinical trial
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity With Bortezomib
Status: Completed, Estimated PCD: 2021-04-06
Product
Bortezomib
Product
NK cells
Clinical trial
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
Status: Terminated, Estimated PCD: 2011-10-06
Product
Oxaliplatin with Gemcitabine
Clinical trial
Neoadjuvant Anti-PD-1 Drug Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Comparison of Every 3 Week Versus Weekly Cisplatin Concurrent With Radiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Correlation With Oxidative Stress Markers
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Status: Recruiting, Estimated PCD: 2027-10-30
Product
ADCT-701
Clinical trial
A Randomized Phase II Trial of TPF Induction Chemotherapy in cN2 Patients With Oral Squamous Cell Carcinoma
Status: Terminated, Estimated PCD: 2023-07-30
Product
TPF Induction Chemotherapy
Clinical trial
A Phase II Study of Circulating Tumor DNA Directed Consolidation Durvalumab (MEDI4736) Following Induction and Concurrent Durvalumab With SABR for Stage I NSCLC. SCION: SABR and Checkpoint Inhibition Of NSCLC
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Status: Recruiting, Estimated PCD: 2025-06-01
Product
4-1BBζ EGFR806-EGFRt
Product
4-1BBζ EGFR806-EGFRt and 4-1BBζ CD19-Her2tG
Clinical trial
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-05-03
Clinical trial
LCCC 1612: P53 Mutational Status and Circulating Free HPV DNA for the Management of HPV-associated Oropharyngeal Squamous Cell Cancers
Status: Completed, Estimated PCD: 2022-12-14
Product
AZD4547
Product
Vistusertib
Product
Selumetinib
Drug
Tamoxifen
Clinical trial
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
Status: Completed, Estimated PCD: 2022-12-22
Drug
T-VEC
Clinical trial
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2019-11-01
Clinical trial
A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
Status: Active (not recruiting), Estimated PCD: 2021-02-24
Product
Topotecan
Clinical trial
A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
Status: Completed, Estimated PCD: 2022-02-01
Drug
FOLFOXIRI
Product
5-Fluoro-uracil
Product
L-folinic
Clinical trial
Single-arm Phase 2 Study to Examine Pembrolizumab and Concurrent Radiation to Induce an Abscopal Effect in Patients With Previously Treated Carcinoma of Unknown Primary (CUP16-268)
Status: Terminated, Estimated PCD: 2021-08-12
Product
PF-07934040
Drug
fluorouracil
Clinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Status: Recruiting, Estimated PCD: 2029-10-01
Product
Vemurafenib
Clinical trial
A Phase 2 Trial of Pharmacological Ascorbate With Concurrent Chemotherapy and Radiation Therapy for Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Radiation Therapy
Clinical trial
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Status: Recruiting, Estimated PCD: 2026-03-01
Drug
cyclophosphamide
Product
MESNA
Product
B7-H3 CAR T cells
Clinical trial
A Cancer Research UK Phase I/II Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of UCB4594 Alone and in Combination With Anti-cancer Treatments in Participants With Advanced Malignancies
Status: Not yet recruiting, Estimated PCD: 2029-11-01
Product
UCB4594
Clinical trial
A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements
Status: Terminated, Estimated PCD: 2021-10-01
Product
Merestinib
Clinical trial
Bronchial Artery Interventional Therapy and Sequential Radiotherapy in the Treatment of Non-resectable, Non-metastatic Central-type Squamous Lung Cancer
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.
Status: Terminated, Estimated PCD: 2021-03-10
Clinical trial
Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
4-1BBζ B7H3-EGFRt-DHFR
Product
second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
Clinical trial
A Phase I/II Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With Receptor Tyrosine Kinase Inhibitor Resistant Renal Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Product
Bicalutamide + Sunitinib
Clinical trial
A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179
Status: Completed, Estimated PCD: 2020-08-10
Clinical trial
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Status: Terminated, Estimated PCD: 2021-10-06
Product
Decitabine
Product
Tetrahydrouridine
Clinical trial
An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of RC48-ADC Combined With JS001 in Postoperative Adjuvant Treatment of HER2-positive Upper Tract Urothelial Carcinoma (UTUC)
Status: Recruiting, Estimated PCD: 2027-12-01
Product
RC48-ADC and JS001
Clinical trial
Osimertinib as Neoadjuvant Therapy in Patients With Resectable Stage II-IIIB EGFR-mutated Lung Squamous Cell Carcinoma: A Single-centre, Single-arm, Phase 2 Trial
Status: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination With Mogamulizumab in Adult Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2019-12-15
Product
KHK2455
Product
Mogamulizumab
Clinical trial
A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2027-04-14
Product
JNJ-86974680
Clinical trial
A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib
Status: Recruiting, Estimated PCD: 2025-07-03
Drug
Lazertinib
Product
Doxycycline
Product
Minocycline
Clinical trial
18F-Clofarabine (CFA) as a PET Imaging Agent to Measure Deoxycytidine Kinase (DCK) Activity in Metastatic Cancer, as a Candidate Predictive Biomarker for Response to DCK-dependent Drugs Such as Gemcitabine
Status: Recruiting, Estimated PCD: 2024-06-05
Product
18F-Clofarabine
Clinical trial
A Phase II Trial of Pembrolizumab in Patients With Non-small Cell Lung Cancer and a Performance Status of 2
Status: Active (not recruiting), Estimated PCD: 2023-02-07
Drug
pembrolizumab
Clinical trial
A Phase II Prospective Immune Neoadjuvant Therapy Study od Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2019-08-28
Clinical trial
A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Status: Recruiting, Estimated PCD: 2027-06-01
Drug
PD-1 monoclonal antibody
Clinical trial
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Drug
Varlilumab
Clinical trial
Single-arm Phase II Clinical Trial to Evaluate the Initial Efficacy and Safety of Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
Sintilimab + Inlyta
Clinical trial
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-04-10
Clinical trial
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: A Pilot, Placebo-controlled, Randomized Trial
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2020-01-09
Clinical trial
A Phase I/II, Open-Label, Single-Arm Study on Safety, Tolerability and Anti-Tumour Efficacy of Orellanine Treatment in Patients With Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Orellanine
Clinical trial
Phase I Study of C6 Ceramide NanoLiposome in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-08-03
Product
Ceramide NanoLiposome
Clinical trial
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure
Status: Active (not recruiting), Estimated PCD: 2023-07-10
Clinical trial
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-02-03
Clinical trial
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-10-31
Product
Direct Oral Anticoagulant
Product
Low Molecular Weight Heparin
Clinical trial
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
Status: Not yet recruiting, Estimated PCD: 2028-07-01
Product
Medroxyprogesterone Acetate
Clinical trial
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-08-13
Product
DM001
Clinical trial
Radiotherapy Dose Escalation Using Intensity-modulated Proton Therapy for Non-small-cell Lung Cancer Patients
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Product
Cisplatin or Carboplatin + Pemetrexed
Clinical trial
ULTRA-HPV Using Circulating Tumor DNA to Risk Adapt Post-operative Therapy for HPV Associated Oropharyngeal Cancer
Status: Not yet recruiting, Estimated PCD: 2031-07-01
Product
H1299 Cell Lysates
Drug
N-803
Clinical trial
Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Imiquimod in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities
Status: Recruiting, Estimated PCD: 2024-08-31
Product
Imiquimod
Product
Belinostat
Clinical trial
A Phase II Trial of Nivolumab in Combination With Ipilimumab to Evaluate Efficacy and Safety Relapsed in Lung Cancer and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint Inhibition
Status: Completed, Estimated PCD: 2022-08-31
Product
Nivolumab, Ipilimumab
Clinical trial
Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2023-06-22
Drug
TKI
Clinical trial
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma, a Randomized, Controlled, Multicenter Clinical Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Anlotinib
Clinical trial
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
Status: Recruiting, Estimated PCD: 2025-01-15
Product
TMZ
Product
Penpulimab
Drug
XELOX
Clinical trial
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression: a Prospective, Open-label, Multicenter, Single-arm Phase II Clinical Study
Status: Not yet recruiting, Estimated PCD: 2027-01-31
Clinical trial
Uncommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-life Practice in First Line Setting
Status: , Estimated PCD: 2024-09-01
Clinical trial
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-02-01
Product
LY4170156
Clinical trial
A Phase 2, Open-label, Non-randomized, Single-center Study to Explore the Diagnostic Performance of [18F]FES PET/CT for the Assessment of Axillary Lymph Node Metastasis in Invasive Lobular Carcinoma of the Breast
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Fluoroestradiol
Clinical trial
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Phase II Trial of Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-05-17
Drug
nivolumab
Product
BMS-986253
Clinical trial
Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Efficacy of Intrathecal Pemetrexed Combined With Tyrosine Kinase Inhibitor for Treating Leptomeningeal Metastasis in EGFR-Mutant NSCLC After Failure of Osimertinib
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
An Open-label Phase II Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours
Status: Recruiting, Estimated PCD: 2033-12-01
Product
[177]Lu-DOTA-TATE
Clinical trial
The Combination of Pembrolizumab and Lenvatinib as Neoadjuvant Treatment for Hepatocellular Carcinoma Patients: a Single Arm Phase II Study
Status: Active (not recruiting), Estimated PCD: 2023-12-15
Product
Pembrolizumab+Lenvatinib
Clinical trial
Shenlingcao Oral Liquid for Patients With Stage II or IIIA Non-small Cell Lung Cancer Receiving Radical Resection: A Pragmatic, Multicenter Randomized Controlled Trial
Status: Completed, Estimated PCD: 2022-03-14
Product
Shenlingcao
Clinical trial
Phase II Trial of Adjuvant De-Escalated Radiation + Concurrent and Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
Status: Active (not recruiting), Estimated PCD: 2023-03-31
Drug
Belzutifan
Clinical trial
Second Line Erlitinib Combination With Gemcitabine Cisplatinum in Non-small Cell Lung Cancer Patients Who Harbored EGFR Sensitive Mutation Developed Resistance After First Line TKI Treatment
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Gemcitabine platinum + Erlotinib
Clinical trial
A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Cabo + Dostarlimab
Clinical trial
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-09-27
Drug
UTD1
Clinical trial
A Phase IV Trial to Confirm the Efficacy of Olaparib in Combination With Bevacizumab as Frontline Treatment of HRD Positive Ovarian Tumors
Status: Recruiting, Estimated PCD: 2027-03-15
Clinical trial
A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Tacrolimus
Product
Myfortic
Product
CellCept
Product
Imuran
Clinical trial
Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Drug
Nimotuzumab
Clinical trial
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors(PRaG9.0)
Status: Not yet recruiting, Estimated PCD: 2026-10-30
Product
ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
Clinical trial
Phase 1 Trial of Dosimetry Guided 212Pb-pentixather Radioligand Therapy in Patients With Atypical Lung Carcinoids and Neuroendocrine Carcinomas
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Product
Lead Pentixather
Product
VX-970
Clinical trial
Traitement Des Carcinomes hépatocellulaires Sur Cirrhose Child A/B7 Par Injection Intra-artérielle hépatique d'Une émulsion de Lipiodol et Idarubicine : Etude de Phase II, Monobras, Multicentrique.
Status: Recruiting, Estimated PCD: 2024-12-18
Product
Idarubicin
Clinical trial
A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2021-11-28
Clinical trial
A Randomized Phase 2 Trial of Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II, and IIIA Non-small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2020-09-16
Clinical trial
Phase I Clinical Trial Testing the Dose Escalation and Expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration for the Management of Pleural Carcinosis
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Cisplatine Teva
Clinical trial
Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-08-14
Product
Durvalumab + Doxorubicin + Ifosfamide
Drug
placebo
Clinical trial
Preliminary Survey of Dietary Practices and Nutritional Status of Patients Treated With Radiochemotherapy for Non-small Cell Lung Carcinoma
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
Blood sample
Clinical trial
Cyclin D1 Based TPF(Docetaxel, Cisplatin and 5-fluorouracil) Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN2(Clinical Node 2) Stage: a Phase II Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Product
TPF group
Clinical trial
A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2022-10-01
Clinical trial
Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer (PRIMM Study)
Status: Recruiting, Estimated PCD: 2024-12-31
Product
chemotherapy + immune checkpoint inhibitors
Drug
fludarabine
Clinical trial
Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2020-01-14
Clinical trial
Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer: a Randomized Phase III Trial (LEPRE Trial)
Status: Recruiting, Estimated PCD: 2029-09-22
Product
Letrozole
Clinical trial
Open, Prospective, Single-center Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma
Status: Completed, Estimated PCD: 2021-03-11
Product
Picato
Clinical trial
Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2018-08-22
Product
Mogamulizumab + Nivolumab
Clinical trial
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)
Status: Active (not recruiting), Estimated PCD: 2026-10-28
Clinical trial
A Phase II Single-arm, Open-label Study of Transarterial Chemoembolization (TACE) in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma (HCC)
Status: Completed, Estimated PCD: 2021-10-12
Product
TACE
Clinical trial
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
MEDI0562
Clinical trial
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
Status: Completed, Estimated PCD: 2022-12-31
Product
nab-Paclitaxel
Clinical trial
A Phase III Clinical Trial of Adjuvant Treatment With Sacituzumab and Zimberelimab for Stage IB-IIIA-IIIB(N2) Previously Resected (R0) Non-small Cell Lung Cancer Patients That Did Not Achieve Pathological Complete Response After Neoadjuvant treatment_ARIAN
Status: Not yet recruiting, Estimated PCD: 2031-06-15
Product
Zimberelimab
Drug
Sacituzumab govitecan
Drug
Tocilizumab
Product
Ipatasertib
Product
Evolocumab
Product
XL092
Product
Camonsertib
Clinical trial
Prospective, Single-arm, Multicenter Clinical Study of Hepatic Artery Infusion Chemotherapy With Donafenib for Adjuvant Treatment of HCC Patients With High Risk of Recurrence After Hepatectomy.
Status: Not yet recruiting, Estimated PCD: 2024-03-01
Product
Folfox Protocol
Product
Donafenib
Clinical trial
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).
Status: Recruiting, Estimated PCD: 2025-06-26
Product
Clindamycin
Product
Chlorhexidine
Clinical trial
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Local Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-07-31
Product
PD-1 Inhibitors
Clinical trial
A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)
Status: Recruiting, Estimated PCD: 2025-12-01
Drug
Spartalizumab
Product
Canakinumab
Clinical trial
A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) Patients
Status: Recruiting, Estimated PCD: 2026-11-15
Product
Placlitaxel
Clinical trial
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Osimertinib + Bevazizumab
Drug
ipilimumab
Product
BMS-986340
Clinical trial
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): "The APA Trial".
Status: Active (not recruiting), Estimated PCD: 2019-12-12
Clinical trial
NVALT 28/ PRL01 Durvalumab and Low-dose Prophylactic Cranial Irradiation (PCI) Versus Durvalumab and Observation in Radically Treated Patients With Stage III Non-small Cell Lung Cancer: A Phase III Randomized Study
Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
A Single Arm, Exploratory Clinical Study on the Neoadjuvant Treatment of Neuroendocrine Cervix Carcinoma With Camrelizumab Combined With Etoposide and Cisplatin
Status: Recruiting, Estimated PCD: 2026-08-31
Product
Karelizumab
Product
Nintedanib
Clinical trial
Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinomas (PDAC) for Better Treatment Selection: A Prospective Study
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Molecular Profiling
Clinical trial
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-27
Clinical trial
Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated With Amivantamab, an EGFR-MET Bispecific Antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
Status: Active (not recruiting), Estimated PCD: 2024-12-15
Drug
lenalidomide
Product
Montelukast
Clinical trial
An Open-Label, Single Arm Study to Evaluate the Efficacy and Safety of Adebrelimab Plus Apatinib as Adjuvant Therapy in Participants With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Adebrelimab + Apatinib
Clinical trial
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SGN-MesoC2 in Subjects With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-11-01
Product
SGN-MesoC2
Clinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF 06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
Status: Terminated, Estimated PCD: 2022-03-30
Product
PF-06952229
Drug
enzalutamide
Clinical trial
A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Product
Carboplatin + Paclitaxel